BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16341038)

  • 1. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia.
    Kratz CP; Böll S; Kontny U; Schrappe M; Niemeyer CM; Stanulla M
    Leukemia; 2006 Feb; 20(2):381-3. PubMed ID: 16341038
    [No Abstract]   [Full Text] [Related]  

  • 2. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.
    Sulong S; Case M; Minto L; Wilkins B; Hall A; Irving J
    Br J Haematol; 2005 Sep; 130(6):964-5. PubMed ID: 16156866
    [No Abstract]   [Full Text] [Related]  

  • 3. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.
    McClure R; Mai M; Lasho T
    Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation.
    Suzuki M; Abe A; Kiyoi H; Murata M; Ito Y; Shimada K; Morishita Y; Kinoshita T; Naoe T
    Leukemia; 2006 Jun; 20(6):1168-9. PubMed ID: 16557239
    [No Abstract]   [Full Text] [Related]  

  • 5. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia.
    Tono C; Xu G; Toki T; Takahashi Y; Sasaki S; Terui K; Ito E
    Leukemia; 2005 Oct; 19(10):1843-4. PubMed ID: 16079889
    [No Abstract]   [Full Text] [Related]  

  • 6. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
    Berger R
    Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
    [No Abstract]   [Full Text] [Related]  

  • 7. JAK the trigger.
    Mahon FX
    Oncogene; 2005 Nov; 24(48):7125-6. PubMed ID: 16007127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
    McLornan D; Percy M; McMullin MF
    Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
    [No Abstract]   [Full Text] [Related]  

  • 9. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
    Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
    Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The V617F JAK2 mutation and the myeloproliferative disorders.
    Percy MJ; McMullin MF
    Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single amino acid change A91V in perforin: a novel, frequent predisposing factor to childhood acute lymphoblastic leukemia?
    Santoro A; Cannella S; Trizzino A; Lo Nigro L; Corsello G; Aricò M
    Haematologica; 2005 May; 90(5):697-8. PubMed ID: 15921391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders.
    Di Ianni M; Moretti L; Del Papa B; Gaozza E; Bell AS; Falzetti F; Tabilio A
    Leukemia; 2006 Oct; 20(10):1895-7. PubMed ID: 16900208
    [No Abstract]   [Full Text] [Related]  

  • 13. Screening of JAK2 V617F mutation in multiple myeloma.
    Fiorini A; Farina G; Reddiconto G; Palladino M; Rossi E; Za T; Laurenti L; Giammarco S; Chiusolo P; Leone G; Sica S
    Leukemia; 2006 Oct; 20(10):1912-3. PubMed ID: 16871278
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis.
    Lay M; Mariappan R; Gotlib J; Dietz L; Sebastian S; Schrijver I; Zehnder JL
    J Mol Diagn; 2006 Jul; 8(3):330-4. PubMed ID: 16825505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the JAK2 V617F mutation on PRV-1 expression.
    Mnjoyan Z; Yoon D; Li J; Delhommeau F; Afshar-Kharghan V
    Haematologica; 2006 Mar; 91(3):411-2. PubMed ID: 16503546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
    Mc Lornan DP; Percy MJ; Jones AV; Cross NC; Mc Mullin MF
    Haematologica; 2005 Dec; 90(12):1696-7. PubMed ID: 16330446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice.
    Funakoshi-Tago M; Tago K; Sumi K; Abe M; Aizu-Yokota E; Oshio T; Sonoda Y; Kasahara T
    J Biol Chem; 2009 May; 284(19):12680-90. PubMed ID: 19289461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients.
    Florensa L; Bellosillo B; Besses C; Puigdecanet E; Espinet B; Pérez-Vila E; Longarón R; Vilà RM; Solé F; Serrano S
    Leukemia; 2006 Oct; 20(10):1903-5. PubMed ID: 16888614
    [No Abstract]   [Full Text] [Related]  

  • 19. JAK2 mutations in myeloproliferative disorders.
    Tefferi A; Lasho TL; Gilliland G
    N Engl J Med; 2005 Sep; 353(13):1416-7; author reply 1416-7. PubMed ID: 16192494
    [No Abstract]   [Full Text] [Related]  

  • 20. FLT3 mutations in childhood acute lymphoblastic leukemia at first relapse.
    Wellmann S; Moderegger E; Zelmer A; Bettkober M; von Stackelberg A; Henze G; Seeger K
    Leukemia; 2005 Mar; 19(3):467-8. PubMed ID: 15674414
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.